CV Lattes
ORCID
Google Scholar Citations
Ministério da Ciência, Tecnologia e Inovação (Brasil). Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Pharmacy-Biochemistry from the University of São Paulo (2001), PhD in Biotechnology from the University of São Paulo (2006), developing viral vector engineering projects for cancer gene therapy. Post-doctorate at the Heart Institute, University of São Paulo (2009), where he worked on gene therapy for cardiac hypertrophy and post-doctorate at the Sylvester Cancer Center, University of Miami (2011), where he developed projects in Cancer Immunotherapy. He is currently a researcher at the National Biosciences Laboratory (LNBio / CNPEM / MCTI), coordinating the the Advanced Biological Research Core, Advanced core for Immunotherapy viral vector laboratory and monoclonal antibody engineering unit. President of the CNPEM Internal Biosafety Committee. Has experience in immunomodulation, antitumor vaccines, immunomodulatory antibodies, engineering and production of viral vectors for gene expression or silencing, engineering of chimeric RNA aptamers. Develops projects in the areas of Biotechnology, virology, gene therapy and cancer immunotherapy. Indicators: published 42 articles in indexed journals. He has 3 patent applications, coordinated 4 FAPESP projects and a CNPq universal project in the area gene therapy and immunotherapy. Coordinates a PRONON project for the development of cell lines that produce biopharmaceuticals. He graduated 4 doctors, 4 masters, supervised 6 post-doctors and more than 30 interns and IC students. He is a collaborating professor at the Faculty of Medical Sciences at UNICAMP and the Faculty of Pharmaceutical Sciences at UNICAMP, teaching subjects and supervising students. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Triple negative breast cancer is characterized by the absence of estrogen, progesterone receptors and low production of the her-2 protein. In this way, hormonal therapies or anti-her2 targeted immunotherapy are ineffective. The available treatment is based on surgical removal, radiotherapy, chemotherapy and currently new protocols have also been explored with the use of PD1 checkpoint inh…
In the last decade, there has been a significant development of therapeutic therapies that act on the mechanisms associated to the control of immune tolerance in T cells, mediated by receptors such as CLTA-4 and PD1, also known as immune checkpoints. The use of checkpoint inhibitors revolutionized medical practice. Furthermore, another important lymphocyte immunosuppression mechanism is r…
Immunotherapy approaches have revolutionized perspectives in the treatment of human cancer. Antibodies known as checkpoint inhibitors act on receptors constitutively expressed on lymphocytes, blocking immunosuppressive mechanisms that antagonize the antitumor response. In this way, boosting lymphocyte activity and potentiation of antitumor immune vigilance is stimulated. In recognition of…
The use of new strategies for treatment of cancer, based on immunotherapy have generated surprising results. Most of these strategies are driven to favor the activity of T cells, which are recognized to play an important role in the control and elimination of tumor cells. T cells have surface receptors that transduce signaling mediators of the activation state. The first activation signal…
(Only some records are available in English at this moment)
Cancer immunotherapy is a strategy that aims to enhance the detection and elimination of tumor cells through direct action on tumor cells or by modulating immune system cells to overcome immunosuppressive mechanisms that can antagonize the antitumor response. In this regard, monoclonal antibodies have been extensively investigated. Examples include the use of ADCC-mediating antibodies, su…
(Only some records are available in English at this moment)
Previos data of our group show the possibility to engineer immunomodulator VLPs with the capacity to potentialize antitumor imumne response. These VLPs derive from retroviral capsides and are encrusted with anchored proteins in the particle surface. We observed that VLPs containing the CD40 ligand, CD40L, activate presenting cells and potencialize the antitumoral immune reponse in animals…
The development of new therapeutic approaches for the treatment of cancer is based on the use of models for evaluation and confirmation of the biological effect. Cell culture assays can provide proofs of concept that warrant testing in more complex biological systems, such as using animal models. In the field of cancer immunotherapy, where the aim is to potentiate cells of the immune syst…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 7 / 5 | Completed research grants |
| 7 / 7 | Ongoing scholarships in Brazil |
| 14 / 7 | Completed scholarships in Brazil |
| 29 / 20 | All research grants and scholarships |
| Associated processes | |